These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography-based Lymph Node Atlas for Salvage Radiotherapy in Patients with Recurrent Prostate Cancer: A Validation of the New NRG Oncology 2020 guideline. Vogel MME; Düsberg M; Stöhrer L; Dewes S; Sage EK; Borm KJ; Gschwend JE; Eiber M; Combs SE; Schiller K Eur Urol Oncol; 2022 Dec; 5(6):668-676. PubMed ID: 36280446 [TBL] [Abstract][Full Text] [Related]
23. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521 [TBL] [Abstract][Full Text] [Related]
24. Pfister D; Haidl F; Nestler T; Verburg F; Schmidt M; Wittersheim M; Steib F; Heidenreich A BJU Int; 2020 Dec; 126(6):679-683. PubMed ID: 32531840 [TBL] [Abstract][Full Text] [Related]
25. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524 [TBL] [Abstract][Full Text] [Related]
27. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by Devos G; Witters M; Moris L; Van den Broeck T; Berghen C; Devlies W; De Meerleer G; Goffin K; Jentjens S; Albersen M; Van Poppel H; Everaerts W; Joniau S World J Urol; 2021 Feb; 39(2):399-406. PubMed ID: 32417995 [TBL] [Abstract][Full Text] [Related]
29. Rational use of Ga-68 PSMA PET-CT according to nomograms and risk groups for the detection of lymph node metastasis in prostate cancer. Madendere S; Kılıç M; Köseoğlu E; Aykanat İC; Eden AB; Coşkun B; Tekkalan FB; Balbay MD Urol Oncol; 2024 Feb; 42(2):29.e9-29.e15. PubMed ID: 38114351 [TBL] [Abstract][Full Text] [Related]
30. The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer. Meijer D; Ettema RH; van Leeuwen PJ; van der Kwast TH; van der Poel HG; Donswijk ML; Oprea-Lager DE; Bekers EM; Vis AN BJU Int; 2023 Mar; 131(3):330-338. PubMed ID: 36069585 [TBL] [Abstract][Full Text] [Related]
31. Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy. Timm B; Farag M; Liodakis P; Angus D; Lim Joon D; Bolton D BJU Int; 2021 May; 127 Suppl 1():23-29. PubMed ID: 33973332 [TBL] [Abstract][Full Text] [Related]
32. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection. Baas DJH; Schilham M; Hermsen R; de Baaij JMS; Vrijhof HJEJ; Hoekstra RJ; Sedelaar JPM; Küsters-Vandevelde HVN; Gotthardt M; Wijers CHW; van Basten JP; Somford DM Prostate Cancer Prostatic Dis; 2022 Mar; 25(1):65-70. PubMed ID: 34471231 [TBL] [Abstract][Full Text] [Related]
33. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581 [TBL] [Abstract][Full Text] [Related]
34. Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients. Onal C; Ozyigit G; Guler OC; Hurmuz P; Torun N; Tuncel M; Dolek Y; Yedekci Y; Oymak E; Tilki B; Akyol F Radiother Oncol; 2020 Oct; 151():222-227. PubMed ID: 32861704 [TBL] [Abstract][Full Text] [Related]
35. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer]. Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428 [TBL] [Abstract][Full Text] [Related]